Viridian Therapeutics, Inc.\DE (VRDN) EBIT: 2014-2025
Historic EBIT for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$40.0 million.
- Viridian Therapeutics, Inc.\DE's EBIT rose 52.07% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 15.93%. This contributed to the annual value of -$299.0 million for FY2024, which is 17.52% down from last year.
- Latest data reveals that Viridian Therapeutics, Inc.\DE reported EBIT of -$40.0 million as of Q3 2025, which was up 62.52% from -$106.8 million recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's EBIT registered a high of -$14.1 million during Q3 2021, and its lowest value of -$106.8 million during Q2 2025.
- For the 3-year period, Viridian Therapeutics, Inc.\DE's EBIT averaged around -$72.2 million, with its median value being -$72.2 million (2024).
- Over the last 5 years, Viridian Therapeutics, Inc.\DE's EBIT had its largest YoY gain of 67.90% in 2021, and its largest YoY loss of 182.37% in 2021.
- Viridian Therapeutics, Inc.\DE's EBIT (Quarterly) stood at -$29.1 million in 2021, then slumped by 68.72% to -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then fell by 22.38% to -$87.5 million in 2024, then skyrocketed by 52.07% to -$40.0 million in 2025.
- Its EBIT was -$40.0 million in Q3 2025, compared to -$106.8 million in Q2 2025 and -$93.9 million in Q1 2025.